Article
Addition of boceprevir to PEG-interferon/ribavirin in HIV-HCV-Genotype-1-coinfected, treatment-experienced patients: efficacy, safety, and pharmacokinetics data from the ANRS HC27 study.
HIV clinical trials - 1 Mar 2016
Poizot-Martin Isabelle, Bellissant Eric, Garraffo Rodolphe, Colson Philippe, Piroth Lionel, Solas Caroline, Renault Alain, Bourlière Marc, Halfon Philippe, Ghosn Jade, Alric Laurent, Naqvi Alissa, Carrieri Patrizia, Molina Jean-Michel
Abstract excerpt
BACKGROUND: Scarce data exist on the efficacy and safety of the PEGylated-interferon/ribavirin/boceprevir regimen in HIV/HCV-coinfected patients who failed to respond to PEGylated-interferon/ribavirin treatment. OBJECTIVES: To evaluate the efficacy and safety of this drug regimen and the impact of the addition of boceprevir(BOC) on atazanavir (ATV) or raltegravir (RAL) pharmacokinetic parameters in a subgroup of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.